CN108610277A - 3-叔胺四取代氧化吲哚化合物及其制备方法 - Google Patents

3-叔胺四取代氧化吲哚化合物及其制备方法 Download PDF

Info

Publication number
CN108610277A
CN108610277A CN201810230684.2A CN201810230684A CN108610277A CN 108610277 A CN108610277 A CN 108610277A CN 201810230684 A CN201810230684 A CN 201810230684A CN 108610277 A CN108610277 A CN 108610277A
Authority
CN
China
Prior art keywords
compound
tertiary amines
present
replace
oxoindole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810230684.2A
Other languages
English (en)
Inventor
刘雄利
徐圣文
杨楷模
刘欢欢
岳静
陈爽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou University
Original Assignee
Guizhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou University filed Critical Guizhou University
Priority to CN201810230684.2A priority Critical patent/CN108610277A/zh
Publication of CN108610277A publication Critical patent/CN108610277A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Indole Compounds (AREA)

Abstract

本发明公开了一种3‑叔胺四取代氧化吲哚化合物，本发明以各种取代的3‑卤氧化吲哚，以无机碱为催化剂，直接以二级环胺作溶剂和反应底物在加温条件下发生3‑叔胺基化反应，获得3‑叔胺四取代氧化吲哚化合物，该类氧化吲哚骨架可以为生物活性筛选提供化合物源，对药物的筛选和制药行业具有重要的应用价值。本发明操作简单易行，原料合成便宜易得，可以在无溶剂中进行，也具有较好的空气稳定性，适用性广，对于各种取代基都有很好的兼容性。

Description

3-叔胺四取代氧化吲哚化合物及其制备方法
技术领域
本发明涉及化学技术领域，尤其是一种3-叔胺四取代氧化吲哚化合物及其制备方法。
背景技术
3-叔胺基氧化吲哚广泛存在于合成药物和天然产物中，吸引了许多化学工作者及医药化学团队的广泛关注，例如，具有抗菌和抗肿瘤活性的天然产物分子psychotrimine，则是从植物psychotria rostrata中分离得到；血管加压素受体拮抗剂SSR-149415也含有3-叔胺基四取代氧化吲哚骨架结构。因此，采用方法学合成更多类型的3-叔胺基氧化吲哚，可以为吲哚类化合物的新药开发和成药性研究奠定物质基础，对药物的筛选和制药行业具有重要的应用价值。
发明内容
本发明的目的是：提供一种3-叔胺四取代氧化吲哚化合物及其制备方法，它是一类重要的医药中间体类似物和药物分子类似物，对药物筛选和制药行业具有重要的应用价值，且其合成方法非常经济简便。
本发明是这样实现的：3-叔胺四取代氧化吲哚化合物，该化合物具有如下通式(Ⅰ)的结构：
式(I)中，R为苄基或取代的苄基；Y为C或氧或硫；n为1或2。
将各种取代的3-卤氧化吲哚，以无机碱为催化剂，直接以二级环胺作溶剂和反应底物在加温条件下发生3-叔胺基化反应，获得3-叔胺四取代氧化吲哚化合物。
合成路线如下：
其中各种取代的3-卤氧化吲哚，二级环胺2的结构式，其取代基满足R为苄基、取代的苄基；Y为C或氧或硫；n为1或2；X为Cl或Br。
所述的无机碱为碳酸钠或碳酸钾或磷酸钠或磷酸钾。
所述的反应温度为50-100℃。
所推测的反应机理如下：
3-卤氧化吲哚1在无机碱催化下，脱去卤化氢生成中间体；中间体然后在二级环胺2亲核进攻下发生3-叔胺基化取代反应得到产物3-叔胺四取代氧化吲哚化合物3，副产物卤化氢被生成的三级胺产物中和成有机盐，促使反应进行完全。
通过采用上述技术方案，以各种取代的3-卤氧化吲哚，以无机碱为催化剂，直接以二级环胺作溶剂和反应底物在加温条件下发生3-叔胺基化反应，获得3-叔胺四取代氧化吲哚化合物，该类氧化吲哚骨架可以为生物活性筛选提供化合物源，对药物的筛选和制药行业具有重要的应用价值。本发明操作简单易行，原料合成便宜易得，可以在无溶剂中进行，也具有较好的空气稳定性，适用性广，对于各种取代基都有很好的兼容性。
附图说明
附图1及附图2为本发明的实施例的化合物3aa-1谱图数据；
附图3及附图4为本发明的实施例的化合物3aa谱图数据；
附图5及附图6为本发明的实施例的化合物3bf-1谱图数据；
附图7及附图8为本发明的实施例的化合物3bb谱图数据
具体实施方式
本发明的实施例1：3-苄基氯取代氧化吲哚(1a)128.5mg(0.5mmol)溶解于吗啉(2mL)中，加入10.6毫克Na2CO3(20mol％)，搅拌下于65℃反应5h(TLC检测)。冷却至室温,直接经硅胶柱层析[洗脱剂：V(乙酸乙酯)/V(石油醚)＝1/10]纯化得淡黄色油状液体3aa140.2mg,收率91％。核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:2.73-2.80(m,4H),3.20(d,J＝12.5Hz,1H),3.37(d,J＝12.5Hz,1H),3.69-3.71(m,4H),6.61(d,J＝7.5Hz,1H),6.81(d,J＝7.5Hz,2H),6.93-7.07(m,4H),7.13-7.16(m,1H),7.34(d,J＝7.5Hz,1H),8.55(br s,1H)；13C NMR(CDCl3,125MHz)δ:40.5,47.5,67.3,72.0,109.8,122.3,125.1,126.4,127.5,128.7,128.8,130.2,134.4,140.9,178.8；HR-MS(ESI-TOF)m/z:Calcd for C19H20N2NaO2{[M+Na]+}331.1417,found 331.125.
化合物3ab至3bh的制备方法同化合物3aa，投料比与化合物3aa相同，可得到化合物3ab至3bh，反应见表1和表2，但需强调的是本发明的化合物不限于表1所表示的内容。
表1为一种3-吗啉或硫代吗啉四取代氧化吲哚的化学结构
本实施例制备化合物3ab:淡黄色油状物；产率88％；1H NMRδ:2.12(s,3H),2.70-2.79(m,4H),3.16(d,J＝12.5Hz,1H),3.32(d,J＝12.5Hz,1H),3.67-3.69(m,4H),6.62(d,J＝7.5Hz,1H),6.69(d,J＝8.0Hz,2H),6.74(d,J＝8.0Hz,2H),7.02-7.05(m,1H),7.11-7.15(m,1H),7.32(d,J＝7.5Hz,1H),8.91(br s,1H)；13C NMRδ:20.8,39.9,47.4,67.2,72.1,109.8,122.1,125.0,128.2,128.7,128.8,130.0,131.2,135.8,141.1,179.1；HR-MS(ESI-TOF)m/z:Calcd for C20H22N2NaO2{[M+Na]+}345.1573,found 345.1573。
本实施例制备化合物3ac:淡黄色油状物；产率89％；1H NMRδ:2.73-2.80(m,4H),3.18(d,J＝12.5Hz,1H),3.33(d,J＝13.0Hz,1H),3.62(s,3H),3.72(s,4H),6.49(d,J＝8.0Hz,2H),6.67(d,J＝7.5Hz,1H),6.74(d,J＝8.5Hz,2H),7.06-7.09(m,1H),7.16-7.19(m,1H),7.36(d,J＝7.5Hz,1H),8.90(br s,1H)；13C NMRδ:39.5,47.5,54.8,67.2,72.1,109.9,112.8,122.1,125.0,126.2,128.7,128.8,131.1,141.1,157.9,179.1；HR-MS(ESI-TOF)m/z:Calcd for C20H22N2NaO3{[M+Na]+}361.1523,found 361.1529。
本实施例制备化合物3ad:淡黄色油状物；产率87％；1H NMRδ:2.71-2.79(m,4H),3.14(d,J＝12.5Hz,1H),3.32(d,J＝12.5Hz,1H),3.68-3.71(m,4H),6.64-6.69(m,3H),7.05-7.08(m,3H),7.15-7.18(m,1H),7.33(d,J＝7.0Hz,1H),8.73(br s,1H)；13C NMRδ:39.9,47.5,67.3,71.9,110.1,120.7,122.5,125.1,128.4,129.1,130.7,132.0,133.5,141.0,178.8；HR-MS(ESI-TOF)m/z:Calcd for C19H19BrN2NaO2{[M+Na]+}409.0522,found409.0521。
本实施例1制备化合物3ae:淡黄色油状物；产率91％；1H NMRδ:2.71-2.79(m,4H),3.17(d,J＝12.5Hz,1H),3.35(d,J＝12.5Hz,1H),3.69-3.71(m,4H),6.60-6.66(m,3H),6.74-6.77(m,2H),7.05-7.08(m,1H),7.15-7.18(m,1H),7.34(d,J＝7.0Hz,1H),8.86(brs,1H)；13C NMRδ:39.6,47.5,67.2,72.1,109.9,114.2(d,JCF＝21.3Hz),122.4,125.0,128.5,129.0,131.6,131.7,141.0,161.5(d,JCF＝243.8Hz),179.0；HR-MS(ESI-TOF)m/z:Calcd for C19H19FN2NaO2{[M+Na]+}349.1323,found 349.1320。
本实施例制备化合物3af:淡黄色油状物；产率91％；1H NMRδ:2.76-2.86(m,4H),3.23(d,J＝12.5Hz,1H),3.40(d,J＝12.5Hz,1H),3.73-3.75(m,4H),6.57(d,J＝10.0Hz,1H),6.65-6.69(m,2H),6.72-6.76(m,1H),6.94-6.98(m,1H),7.08-7.11(m,1H),7.17-7.20(m,1H),7.36(d,J＝6.0Hz,1H),8.84(br s,1H)；13C NMRδ:40.1,47.4,67.3,71.8,110.0,113.4(d,JCF＝21.3Hz),113.5,117.0(d,JCF＝21.3Hz),122.4,125.0,126.0,128.3,128.8,128.9,129.0,137.1,140.9,161.9(d,JCF＝223.8Hz),178.7；HR-MS(ESI-TOF)m/z:Calcdfor C19H19FN2NaO2{[M+Na]+}349.1323,found 349.1327。
本实施例制备化合物3bb:淡黄色油状物；产率93％；1H NMRδ:2.14(s,3H),2.67(s,4H),3.01(s,4H),3.17(d,J＝12.5Hz,1H),3.27(d,J＝12.5Hz,1H),6.62-6.67(m,3H),6.74(d,J＝8.0Hz,2H),7.04-7.07(m,1H),7.14-7.16(m,1H),7.31(d,J＝7.5Hz,1H),8.63(br s,1H)；13C NMRδ:20.9,28.5,40.5,49.8,72.9,109.9,122.3,124.9,128.2,128.7,129.1,130.1,131.1,135.9,140.8,179.3；HR-MS(ESI-TOF)m/z:Calcd for C20H22N2NaOS{[M+Na]+}361.1345,found 361.1352。
本实施例制备化合物3be:淡黄色油状物；产率95％；1H NMRδ:2.67-2.69(m,4H),2.98-3.05(m,4H),3.18(d,J＝12.5Hz,1H),3.29(d,J＝12.5Hz,1H),6.60-6.66(m,3H),6.71-6.74(m,2H),7.06-7.09(m,1H),7.16-7.19(m,1H),7.33(d,J＝7.5Hz,1H),8.66(brs,1H)；13C NMRδ:28.5,40.2,49.8,72.9,109.9,114.3(d,JCF＝21.3Hz),122.5,124.9,128.9(d,JCF＝20.0Hz),131.6,131.7,140.7,161.5(d,JCF＝243.8Hz),179.1；HR-MS(ESI-TOF)m/z:Calcd for C19H19FN2NaOS{[M+Na]+}365.1094,found 365.1099。
本实施例制备化合物3bg:淡黄色油状物；产率90％；1H NMRδ:1.16(s,9H),2.67(s,4H),3.01-3.03(m,4H),3.20-3.27(m,2H),6.62(d,J＝7.5Hz,1H),6.72(d,J＝8.0Hz,2H),6.99(d,J＝8.0Hz,2H),7.02-7.05(m,1H),7.12-7.15(m,1H),7.26-7.29(m,1H),8.64(br s,1H)；13C NMRδ:28.5,31.2,34.1,40.3,49.7,72.7,109.9,122.2,124.3,124.9,128.7,129.1,129.8,131.2,140.8,149.2,179.3；HR-MS(ESI-TOF)m/z:Calcd forC23H28N2NaOS{[M+Na]+}403.1815,found 403.1815。
本实施例制备化合物3bh:淡黄色油状物；产率91％；1H NMRδ:2.68-2.70(m,4H),3.02-3.04(m,4H),3.18(d,J＝12.5Hz,1H),3.27(d,J＝10.0Hz,1H),6.66(d,J＝7.5Hz,1H),6.74(d,J＝8.0Hz,1H),6.82-6.86(m,1H),6.91(s,1H),7.06-7.09(m,1H),7.15-7.20(m,2H),7.27-7.30(m,1H),8.53(br s,1H)；13C NMRδ:28.6,40.5,49.8,72.6,110.1,121.4,122.5,124.9,128.6,128.9,129.0,129.1,129.6,133.2,136.8,140.7,178.7；HR-MS(ESI-TOF)m/z:Calcd for C19H19BrN2NaOS{[M+Na]+}425.0294,found 425.0290。
化合物3aa-1至3bi-1的制备方法同化合物3aa，投料比与化合物3aa相同，可得到化合物3aa-1至3bi-1，反应见表1和表2，但需强调的是本发明的化合物不限于表2所表示的内容。
表2表1为一种3-哌啶或吡咯烷氧化吲哚的化学结构
本实施例制备化合物3aa-1:淡黄色油状物；产率90％；1H NMR(CDCl3,500MHz)δ:1.43(d,J＝5.0Hz,2H),1.55-1.60(m,4H),2.68-2.70(m,4H),3.25(d,J＝12.5Hz,1H),3.35(d,J＝12.5Hz,1H),6.60(d,J＝7.5Hz,1H),6.79-6.81(m,2H),6.91-6.94(m,2H),6.96-7.00(m,1H),7.01-7.04(m,1H),7.10-7.14(m,1H),7.35(d,J＝7.5Hz,1H),8.69(br s,1H)；13C NMR(CDCl3,125MHz)δ:24.6,26.4,41.1,48.2,72.7,109.6,121.9,125.0,126.2,127.4,128.4,129.5,130.2,134.9,140.9,179.6；HRMS(ESI-TOF)m/z:Calcd.forC20H22N2NaO[M+Na]+:329.1630；Found:329.1639。
本实施例制备化合物3ab-1:淡黄色油状物；产率93％；1H NMR(CDCl3,500MHz)δ:1.42(s,2H),1.55-1.58(m,4H),2.13(s,3H),2.68(s,4H),3.22(d,J＝12.5Hz,1H),3.31(d,J＝12.5Hz,1H),6.60(d,J＝7.5Hz,1H),6.68(d,J＝8.0Hz,2H),6.73(d,J＝7.5Hz,2H),7.01-7.04(m,1H),7.11-7.13(m,1H),7.33(d,J＝7.5Hz,1H),8.59(br s,1H)；13C NMR(CDCl3,125MHz)δ:20.9,24.7,26.4,40.6,48.1,72.7,109.6,121.9,125.0,128.1,128.3,129.6,130.1,131.7,135.6,141.0,179.6；HRMS(ESI-TOF)m/z:Calcd.for C21H24N2NaO[M+Na]+:343.1786；Found:343.1787。
本实施例制备化合物3ac-1:淡黄色油状物；产率87％；1H NMR(CDCl3,500MHz)δ:1.47(s,2H),1.60-1.62(m,4H),2.72(s,4H),3.24(d,J＝12.5Hz,1H),3.33(d,J＝12.5Hz,1H),3.66(s,3H),6.52(d,J＝8.5Hz,2H),6.65(d,J＝7.5Hz,1H),6.74(d,J＝8.5Hz,2H),7.06-7.09(m,1H),7.16-7.19(m,1H),7.38(d,J＝7.5Hz,1H),8.26(br s,1H)；13C NMR(CDCl3,125MHz)δ:24.7,26.5,40.2,48.2,54.9,72.8,109.6,112.8,122.0,125.1,126.8,128.4,129.7,131.2,140.9,157.9,179.5；HRMS(ESI-TOF)m/z:Calcd.for C21H24N2NaO2[M+Na]+:359.1735；Found:359.1731。
本实施例制备化合物3ad-1:淡黄色油状物；产率85％；1H NMR(CDCl3,500MHz)δ:1.45(d,J＝5.0Hz,2H),1.58-1.60(m,4H),2.09(s,3H),2.73(s,4H),3.34(s,2H),6.62(d,J＝8.0Hz,1H),6.84-6.98(m,5H),7.12-7.15(m,1H),7.20(d,J＝7.5Hz,1H),7.82(br s,1H)；13C NMR(CDCl3,125MHz)δ:20.2,24.7,26.5,36.4,48.1,72.2,109.4,122.0,125.0,125.4,126.4,128.4,130.0,130.3,133.7,137.4,140.7,179.5；HRMS(ESI-TOF)m/z:Calcd.for C21H24N2NaO[M+Na]+:343.1786；Found:343.1786。
本实施例制备化合物3ae-1:淡黄色油状物；产率92％；1H NMR(CDCl3,500MHz)δ:1.43(d,J＝5.5Hz,2H),1.56-1.59(m,4H),2.65-2.70(m,4H),2.22(d,J＝13.0Hz,1H),3.31(d,J＝12.5Hz,1H),6.59-6.65(m,3H),6.73-6.76(m,2H),7.03-7.06(m,1H),7.13-7.16(m,1H),7.35(d,J＝7.5Hz,1H),8.85(br s,1H)；13C NMR(CDCl3,125MHz)δ:24.6,26.4,40.2,48.2,72.8,109.8,114.2(d,JCF＝21.3Hz),122.1,125.0,128.6,129.3,131.6,140.9,161.5(d,JCF＝242.5Hz),179.6；HRMS(ESI-TOF)m/z:Calcd.for C20H21FN2NaO[M+Na]+:347.1536；Found:347.1542。
本实施例制备化合物3af-1:淡黄色油状物；产率90％；1H NMR(CDCl3,500MHz)δ:1.42-1.45(m,2H),1.56-1.61(m,4H),2.69(s,4H),3.19(d,J＝12.5Hz,1H),3.31(d,J＝12.0Hz,1H),6.61(d,J＝8.0Hz,1H),6.68(d,J＝8.5Hz,2H),7.03-7.09(m,3H),7.13-7.17(m,1H),7.33(d,J＝7.5Hz,1H),7.86(br s,1H)；13C NMR(CDCl3,125MHz)δ:24.6,26.5,40.5,48.2,72.4,109.7,120.5,122.2,125.0,128.7,129.3,130.6,132.0,134.0,140.6,178.8；HRMS(ESI-TOF)m/z:Calcd.for C20H21BrN2NaO[M+Na]+:407.0735；Found:407.0746。
本实施例制备化合物3ag-1:淡黄色油状物；产率93％；1H NMR(CDCl3,500MHz)δ:1.43(d,J＝5.0Hz,2H),1.55-1.60(m,4H),2.65-2.70(m,4H),3.21(d,J＝12.5Hz,1H),3.31(d,J＝12.5Hz,1H),6.64(d,J＝8.0Hz,1H),6.72(d,J＝8.5Hz,2H),6.89(d,J＝8.5Hz,2H),7.02-7.06(m,1H),7.13-7.16(m,1H),7.33(d,J＝7.0Hz,1H),8.76(br s,1H)；13C NMR(CDCl3,125MHz)δ:24.6,26.4,40.4,48.1,72.6,109.8,122.1,125.0,127.5,128.6,129.2,131.6,132.2,133.4,140.8,179.5；HRMS(ESI-TOF)m/z:Calcd.for C20H21ClN2NaO[M+Na]+:363.1240；Found:363.1240。
本实施例制备化合物3ah-1:淡黄色油状物；产率89％；1H NMR(CDCl3,500MHz)δ:1.44(s,2H),1.57-1.59(m,4H),2.69(d,J＝5.0Hz,4H),3.25(d,J＝12.5Hz,1H),3.33(d,J＝12.5Hz,1H),6.50(d,J＝10.0Hz,1H),6.61-6.65(m,2H),6.68-6.71(m,1H),6.87-6.92(m,1H),7.02-7.05(m,1H),7.12-7.16(m,1H),7.32(d,J＝7.0Hz,1H),8.80(br s,1H)；13CNMR(CDCl3,125MHz)δ:24.7,26.5,40.8,48.2,72.5,109.9,113.2,113.4,117.0(d,JCF＝21.3Hz),122.2,125.0,126.1,128.7,128.8,129.2,137.6,141.0,162.0(d,JCF＝243.8Hz),179.5；HRMS(ESI-TOF)m/z:Calcd.for C20H21FN2NaO[M+Na]+:347.1536；Found:347.1538。
本实施例制备化合物3ai-1:淡黄色油状物；产率87％；1H NMR(CDCl3,500MHz)δ:1.43-1.46(m,2H),1.58(d,J＝6.0Hz,4H),2.70(s,4H),3.22(d,J＝15.5Hz,1H),3.29(d,J＝15.5Hz,1H),6.65(d,J＝9.5Hz,1H),6.77-6.85(m,2H),6.93(s,1H),7.04-7.08(m,1H),7.13-7.18(m,2H),7.32(d,J＝9.0Hz,1H),8.51(br s,1H)；13C NMR(CDCl3,125MHz)δ:24.6,26.4,40.7,48.2,72.4,109.8,121.3,122.2,125.0,128.7,128.9,129.0,129.1,129.4,133.2,137.4,140.8,179.1；HRMS(ESI-TOF)m/z:Calcd.for C20H21BrN2NaO[M+Na]+:407.0735；Found:407.0741。
本实施例制备化合物3ba-1:淡黄色油状物；产率85％；1H NMR(CDCl3,500MHz)δ:1.22-1.27(m,4H),2.74-2.78(m,2H),2.92-2.95(m,2H),3.30(d,J＝12.5Hz,1H),3.50(d,J＝12.5Hz,1H),6.59(d,J＝7.5Hz,1H),6.74-6.81(m,1H),6.85(d,J＝7.0Hz,1H),6.96-7.04(m,4H),7.10-7.12(m,1H),7.39(d,J＝7.5Hz,1H),8.22(br s,1H)；13C NMR(CDCl3,125MHz)δ:23.2,42.5,47.0,70.2,109.5,122.1,125.0,126.3,127.4,127.5,128.5,129.8,130.2,130.4,134.9,140.6,179.4；HRMS(ESI-TOF)m/z:Calcd.for C19H20N2NaO[M+Na]+:315.1473；Found:315.1477。
本实施例制备化合物3bb-1:淡黄色油状物；产率90％；1H NMR(CDCl3,500MHz)δ:1.73(s,4H),2.13(s,3H),2.73-2.76(m,2H),2.89-2.91(m,2H),3.27(d,J＝12.5Hz,1H),3.44(d,J＝12.5Hz,1H),6.60(d,J＝7.5Hz,1H),6.71-6.76(m,4H),6.99-7.03(m,1H),7.09-7.13(m,1H),7.36(d,J＝7.0Hz,1H),8.83(br s,1H)；13C NMR(CDCl3,125MHz)δ:20.9,23.2,42.0,46.9,70.2,109.7,122.0,124.9,128.2,128.4,129.8,130.0,131.7,135.6,140.8,179.8；HRMS(ESI-TOF)m/z:Calcd.for C20H22N2NaO[M+Na]+:329.1630；Found:329.1630。
本实施例制备化合物3bc-1:淡黄色油状物；产率85％；1H NMR(CDCl3,500MHz)δ:1.78(s,4H),2.77-2.79(m,2H),2.92-2.94(m,2H),3.29(d,J＝12.5Hz,1H),3.46(d,J＝13.0Hz,1H),3.65(s,3H),6.52(d,J＝8.5Hz,2H),6.66(d,J＝7.5Hz,1H),6.78(d,J＝9.0Hz,2H),7.05-7.08(m,1H),7.15-7.18(m,1H),7.41(d,J＝7.0Hz,1H),8.59(br s,1H)；13C NMR(CDCl3,125MHz)δ:23.3,41.7,47.0,54.9,70.4,109.7,112.8,122.1,125.0,126.9,128.5,130.0,131.2,140.8,158.0,179.8；HRMS(ESI-TOF)m/z:Calcd.for C20H22N2NaO2[M+Na]+:345.1579；Found:345.1579。
本实施例制备化合物3be-1:淡黄色油状物；产率87％；1H NMR(CDCl3,500MHz)δ:1.74(s,4H),2.73-2.75(m,2H),2.89-2.91(m,2H),3.27(d,J＝13.0Hz,1H),3.45(d,J＝12.5Hz,1H),6.60-6.65(m,3H),6.77-6.80(m,2H),7.02-7.05(m,1H),7.12-7.16(m,1H),7.37(d,J＝7.0Hz,1H),8.90(br s,1H)；13C NMR(CDCl3,125MHz)δ:23.2,41.6,46.9,70.2,109.8,114.2(d,JCF＝21.3Hz),122.2,124.9,128.7,129.5,131.6,140.7,161.5(d,JCF＝243.8Hz),179.8；HRMS(ESI-TOF)m/z:Calcd.for C19H19FN2NaO[M+Na]+:333.1379；Found:333.1387。
本实施例制备化合物3bf-1:淡黄色油状物；产率90％；1H NMR(CDCl3,500MHz)δ:1.75(s,4H),2.73-2.75(m,2H),2.89-2.92(m,2H),3.25(d,J＝12.5Hz,1H),3.43(d,J＝12.5Hz,1H),6.63(d,J＝8.0Hz,1H),6.71(d,J＝8.0Hz,2H),7.02-7.05(m,1H),7.08(d,J＝8.0Hz,2H),7.13-7.16(m,1H),7.36(d,J＝7.5Hz,1H),8.54(br s,1H)；13C NMR(CDCl3,125MHz)δ:23.3,41.9,47.0,70.1,109.9,120.6,122.3,124.9,128.8,129.5,130.6,132.0,133.9,140.6,179.4；HRMS(ESI-TOF)m/z:Calcd.for C19H19BrN2NaO[M+Na]+:393.0578；Found:393.0571。
本实施例制备化合物3bi-1:淡黄色油状物；1H NMR(CDCl3,500MHz)δ:1.76(s,4H),2.74-2.77(m,2H),2.92-2.94(m,2H),3.26(d,J＝13.0Hz,1H),3.44(d,J＝12.5Hz,1H),6.63(d,J＝7.5 Hz,1H),6.81-6.87(m,2H),6.96(s,1H),7.04-7.07(m,1H),7.14-7.17(m,2H),7.36(d,J＝7.5 Hz,1H),8.11(br s,1H)；13C NMR(CDCl3,125 MHz)δ:23.3,42.1,47.0,69.9,109.7,121.4,122.3,125.0,128.8,129.0,129.4,129.5,133.2,137.3,140.4,179.0；HRMS(ESI-TOF)m/z:Calcd.for C19H19BrN2NaO[M+Na]+:393.0578；Found:393.0582。

Claims (4)

1.一种3-叔胺四取代氧化吲哚化合物，其特征在于：该化合物具有如通式(Ⅰ)所示的结构：
式(I)中，R为苄基或取代的苄基；Y为C或氧或硫；n为1或2。
2.一种如权利要求1所述的3-叔胺四取代氧化吲哚化合物的制备方法，其特征在于：将各种取代的3-卤氧化吲哚，以无机碱为催化剂，直接以二级环胺作溶剂和反应底物在加温条件下发生3-叔胺基化反应，获得3-叔胺四取代氧化吲哚化合物。
合成路线如下：
反应机理如下：
其中，R为苄基或取代的苄基；Y为C或氧或硫；n为1或2；X为氯或溴。
3.根据权利要求2所述的3-叔胺四取代氧化吲哚化合物的制备方法，其特征在于：所述的无机碱为碳酸钠、碳酸钾、磷酸钠或磷酸钾。
4.根据权利要求2所述的3-叔胺四取代氧化吲哚化合物的制备方法，其特征在于：所述的反应温度为50-100℃。
CN201810230684.2A 2018-03-20 2018-03-20 3-叔胺四取代氧化吲哚化合物及其制备方法 Pending CN108610277A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810230684.2A CN108610277A (zh) 2018-03-20 2018-03-20 3-叔胺四取代氧化吲哚化合物及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810230684.2A CN108610277A (zh) 2018-03-20 2018-03-20 3-叔胺四取代氧化吲哚化合物及其制备方法

Publications (1)

Publication Number Publication Date
CN108610277A true CN108610277A (zh) 2018-10-02

Family

ID=63658953

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810230684.2A Pending CN108610277A (zh) 2018-03-20 2018-03-20 3-叔胺四取代氧化吲哚化合物及其制备方法

Country Status (1)

Country Link
CN (1) CN108610277A (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101203489A (zh) * 2005-06-24 2008-06-18 霍夫曼-拉罗奇有限公司 羟吲哚衍生物
US20080318923A1 (en) * 2005-01-28 2008-12-25 Taisho Pharmaceutical Co., Ltd. 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle
CN101516366A (zh) * 2006-09-21 2009-08-26 霍夫曼-拉罗奇有限公司 作为抗癌剂的羟吲哚衍生物
CN106928122A (zh) * 2017-03-07 2017-07-07 贵州大学 3‑烷氧基季碳氧化吲哚及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080318923A1 (en) * 2005-01-28 2008-12-25 Taisho Pharmaceutical Co., Ltd. 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle
CN101203489A (zh) * 2005-06-24 2008-06-18 霍夫曼-拉罗奇有限公司 羟吲哚衍生物
CN101516366A (zh) * 2006-09-21 2009-08-26 霍夫曼-拉罗奇有限公司 作为抗癌剂的羟吲哚衍生物
CN106928122A (zh) * 2017-03-07 2017-07-07 贵州大学 3‑烷氧基季碳氧化吲哚及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SATOSHI MIZUTA，ET AL: "Ionic Liquid-Mediated Hydrofluorination of o-Azaxylylenes Derived from 3‑Bromooxindoles", 《ORG. LETT.》 *

Similar Documents

Publication Publication Date Title
CN107383030A (zh) 姜黄酮拼接3,3’‑吡咯双螺环氧化吲哚化合物及其制备方法及应用
CN101591275A (zh) 一种合成1,6-烯炔类化合物的方法
EP0034461B1 (en) Aromatic aminoethanol compounds and salts thereof, pharmaceutical compositions comprising them and processes for their production
CN110143918A (zh) 3,4-二氢-3-(2-羟基苯甲酰)-2(1h)-喹啉酮活性骨架及合成方法和应用
CN101245046B (zh) 3-吲哚-1-丙烯类化合物、合成方法和用途
CN108610277A (zh) 3-叔胺四取代氧化吲哚化合物及其制备方法
CN107805253B (zh) 手性螺环氧化吲哚类化合物及其合成方法
CN107573376B (zh) 一种烷基硫(硒)代膦酸酯的制备方法
CN109705130A (zh) 二氢色原酮骨架拼接多环吡咯螺环氧化吲哚化合物及其制备方法及应用
CN104557957B (zh) 螺‑氧化吲哚环氧乙烷衍生物的合成方法
CN111072605B (zh) 一种氟烷基取代的苯并呋喃衍生物或吲哚衍生物的制备方法
CN105254626B (zh) 一种六氢吡啶‑2,3‑并吲哚‑2‑酮类化合物及其制备方法及应用
CN106188046A (zh) 一种碘促进的3‑芳硫基咪唑并[1,5‑a]N‑杂环化合物的合成方法
JP5665041B2 (ja) ヨードニウム化合物、その製造方法、及び官能基化スピロ環状化合物とその製造方法
CN109503658A (zh) 一种(e)-3-芳基-1-氟-1,3-丁二烯膦酸酯类化合物及其合成方法和应用
CN113444101B (zh) 环戊环并色满酮拼接双螺环茚二酮氧化吲哚类化合物及其制备方法及应用
CN105949119B (zh) 一种合成多取代2(1h)-喹啉酮类化合物的方法
Chen et al. Enantioselective synthesis of (+)-brevipolide H
CN105481781B (zh) 化合物及其制备方法和应用
CN110642831B (zh) 一种在丙酮诱导下对芳烃或者杂芳烃进行氟烷基化的方法
CN101287711A (zh) 1-取代-5-酰基咪唑化合物的制备方法
CN104693194B (zh) 3‑(2‑丙烯酸酯)‑3ˊ‑硝基异噁唑氧化吲哚化合物及其制备方法及应用
CN103804273B (zh) 氧化吲哚与茚三酮双季碳拼接衍生物及其制备方法
CN110028519A (zh) 山酮素骨架拼接双螺环氧化吲哚化合物及其制备方法及应用
CN108727235A (zh) 制备三氟甲基高烯丙基或联烯基硫醚的新方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20181002

RJ01 Rejection of invention patent application after publication